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Abstract
BACKGROUND: Coronavirus (CoV) disease (COVID-19) has become a global health pandemic by early 2020; it has 
pushed the health-care system to its limit. From the initial estimates, 15% of COVID-19 patients caused by severe 
acute respiratory CoV 2 syndrome present with severe symptoms and requires hospitalization or even intensive 
care. There is no specific treatment against COVID-19, particularly for those with severe symptoms. Desperation 
caused by COVID-19 has driven clinicians to try an alternative therapies with little or even no-evidence previously. 
Convalescent plasma therapy (CPT) has emerged as a promising COVID-19 therapy.
AIM: We aimed to review current state of convalescent plasma therapy. 
METHODS: We summarize the historical CPT, COVID-19 pathology and evaluate potential of CPT for COVID-19; 
raising the question regarding routinely administrating CPT to the COVID-19 patients, whether it is safe and effective.
RESULTS: From cases in Indonesia and other countries, there is bunch of examples that healthcare workers being 
negatively stigmatized in case of COVID-19. They lost their rights to have a normal life in this pandemic era. A 
reasonable basis is found in many literatures to advocate the CPT. Convalescent plasma from COVID-19 patients 
who had been recovered with high neutralizing antibody titers was reported to be effective on transfusion to other 
COVID-19 patients.
CONCLUSION: CPT is one good option to treat COVID-19 patients, but it not without risk; many potential candidate 
treatment that promising in theory but somehow fall apart when translated into clinical study; only time will tell, 
including our ongoing CPT clinical study.
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Introduction
Coronavirus (CoV) disease (COVID-19) is 
currently a global health problem, but until recently, 
there is no specific therapy for COVID-19 [1]. Since 
December 2019, pneumonia cases caused by severe 
acute respiratory syndrome-CoV-2 (SARS-CoV-2) until 
May 24, 2020, have reported total 5,429,234 cases 
with 344,448 deaths and 2,259,882 recovered, with a 
percentage of case fatality rate (CFR) in the world of 
6.48% [2]. The most cases were found in the USA with 
1,667,284 cases, followed by Brazil with 349,113 cases 
then Russia with 344,481 cases, while the Republic of 
China, where the virus originated, was in the 14 ranks 
with 82,974 cases. The highest death cases were in the 
USA which was 98,691 people, followed by the UK with 
36,675 people and Italy 32,735 people; while deaths 
in the Republic of China reached 4,634 cases [2]. In 
Indonesia, as of May 24, 2020, there were 22,271 
reported cases, with a total of 1372 deaths and 5402 
recovered [3]. Since March 11, 2020, the World Health 
Organization (WHO) has established pandemic status 
for the COVID-19 case [4].
The COVID-19 case was first identified in 
Indonesia in early March 2020, which infected two 
patients, then spread to all provinces in Indonesia [5], [6]. 
The CFR rate in Indonesia reached 6.21%, surpassing 
the Republic of China with 5.52% or even almost equal 
with the world (6.48%). Patients who were confirmed 
positive, most came from Jakarta, which reached 6515 
cases, East Java Province ranks second with 3596 
cases, followed by West Java Province with 2045 
cases [3]. There were 2045 positive confirmed cases in 
West Java Province, with recovered of 471 people and 
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a death toll of 127 [3]. Until May 22, 2020, Dr. Hasan 
Sadikin Hospital (RSHS), Bandung, West Java, had 
treated 308 patients in monitoring (PIM) cases, with 
confirmed COVID-19 positive of 75 cases; there were 
57 PIM death cases, with confirmed COVID-19 positive 
of 23 cases [7]. The therapy used in RSHS refers to 
the COVID-19 therapy protocol from the Indonesian 
Lung Association, including chloroquine phosphate, 
oseltamivir, and other supportive therapies [8].
Globally, all health authorities are planning 
(and constantly scrambling) for the increased growing 
number of hospitalized patients. With the absence 
of any detectable natural immunity to this CoV in the 
population, and no known therapy or vaccinations, 
management has been largely supportive to date [9]. 
Nevertheless, a number of therapies are being 
investigated and implemented by researchers and 
clinicians. Those clinical trials including: Retroviral drugs 
such as lopinavir/ritonavir and remdesivir, combination 
of hydroxychloroquine and azithromycin, and anti-
malarial drug chloroquine [10]. The other modality that 
has been investigated and advocated for alternative 
treatment of COVID-19 is convalescent plasma therapy 
(CPT) in the world, as well as in Indonesia [1], [11].
CPT has been known and used to preventing 
viral diseases such as mumps, measles, and 
poliomyelitis [12], [13]. This therapy also has been used 
effectively in the treatment of H5N1 avian influenza [14], 
H1N1 influenza [15], SARS [16], and Middle East 
respiratory syndrome (MERS) [17], in which CPT has 
been found to be both safe and effective. Our center in 
Bandung, has just started to begin the CPT clinical trial 
for patients with severe COVID-19 (Ethical approval 
No. LB.02.01/X.6.5/94/2020).
SARS-CoV-2
CoV disease 2019 (COVID-19) is a form of 
respiratory illness caused by severe acute respiratory 
syndrome CoV 2 (SARS-CoV-2); CoV is a capsule-
positive, single-stranded RNA virus, included in the 
Coronaviridae family belong to the Orthocoronavirinae 
subfamily, and has a “crown-like” in its surface 
area [18]. CoV is included in the genus beta-CoV as 
(SARS; emerged in China in 2003), (MERS; appeared 
in Saudi Arabia in 2012) but has different biological and 
virulence characteristics [19]. Bats are considered as 
the natural host reservoir of SARS-like CoV. However, 
the origin or natural host for the 2019-nCoV is not clear, 
it might come from a kind of wild life [20]. SARS-CoV-2 
is as big as 125 nm in diameter; they are also relatively 
large for the viruses that use RNA to replicate; with 
30,000 genetic bases, the largest genomes of all RNA 
viruses. SARS-CoV-2 has 29,891 nucleotides which 
encode 9860 amino acids [18]. Their genomes are more 
than 3 times as big as those of HIV and hepatitis C, 
and more than twice influenza’s [21]. SARS-CoV-2 is 
so far estimated to have a rate of <25 mutations per 
year, compare to influenza’s 50 [22]. The fatality rates 
of both SARS and MERS are much higher, 9.6% and 
34.4%, respectively [23], [24]. Infographic comparison 
of the three major genus beta-CoV, SARS, and MERS 
compared to COVID-19 is shown in Figure 1.
Figure 1: Infographic comparison of the three major genus beta-
coronavirus, namely: severe acute respiratory syndrome (emerged in 
China in 2002), Middle East respiratory syndrome (appeared in Saudi 
Arabia in 2012) and coronavirus disease 2019 (COVID-19; appeared 
in China in late 2019)
All CoVs contain very specific genes in open 
reading frame 1 (ORF1) downstream regions that 
encode proteins for viral replication, nucleocapsid, and 
spikes formation [25]. The glycoprotein spikes on the 
outer surface of CoVs are responsible for the attachment 
and entry of the virus to host cells. The receptor-
binding domain (RBD) is loosely attached among virus; 
therefore, the virus may infect multiple hosts [26], [27]. 
SARS-CoV-2 possesses the typical CoV structure with 
spike protein and also expressed other polyproteins, 
nucleoproteins, and membrane proteins, such as RNA 
polymerase, 3-chymotrypsin-like protease, papain-
like protease, helicase, glycoprotein, and accessory 
proteins [28], [29]. The 394 glutamine residue in the RBD 
region of SARS-CoV-2 is recognized by the critical lysine 
31 residue on the human angiotensin converting enzyme 
2 (ACE2) receptor [30]. According to current evidence, 
SARS-CoV-2 is primarily transmitted between the people 
through respiratory droplets and contact routes.
Although SARS-CoV-2 shares 79% of 
its genome with SARS-CoV, it presumably more 
contagious [31]. As recently Indonesia submitted three 
full sequence genome (ID: EIJK2444, EIJK 0141 and 
EIJK 0317) to Global Initiative on Sharing AvIan flu Data 
(GISAID); interestingly, all COVID-19 in Indonesia is 
originated from the Republic of China and been mutated 
as non-synonymous. For EIJK2444, travel from the 
Republic of China to Australia and Japan, finally arrived 
in Indonesia; it mutated in the amino acid Threonine at 
position 76, converting it to Isoleusin in the amino acid 
sequence of protein S. For EIJK0141, travel from the 
Republic of China to United Kingdom and United State, 
and finally arrived in Indonesia; it mutated in the amino 
acid Serine at position 2103, converting it to Phenilalanine 
in the amino acid sequence of protein ORF1a. For 
EIJK0317, travel from the Republic of China to United 
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Kingdom, United State and United Arab Emirates, and 
finally arrived in Indonesia; it mutated in the amino acid 
Isoleucine at position 461, converting it to Valine in the 
amino acid sequence of protein ORF1a [32].
Both of SARS-CoVs enter the host cells 
through ACE2 receptor [30]. The SARS-CoV-2 
predominantly infects the lower airways and binds to 
ACE2 on surface alveolar epithelial cells. Both viruses 
are potent inducers of inflammatory cytokines. The 
cytokine storm or cytokine cascade is the postulated 
mechanism for organ damage. The virus activates 
immune cells, induces the secretion of inflammatory 
cytokines and chemokines into pulmonary vascular 
endothelial cells [33]. There were 14 cytokines that 
significantly elevated on admission in COVID-19 cases. 
Moreover, IP-10, MCP-3, and IL-1ra were significantly 
higher in severe cases and highly associated with the 
PaO2/FaO2 and Murray score [34].
Pathology of COVID-19
The S protein on CoV surface specifically 
recognizes the spike protein in ACE2 of the exposed 
cell and after binding, the virus enters the cell thereby 
infected the cell [30]. Unfortunately, the ACE2 receptor 
is widely distributed on the human cells surface, 
especially at AT2 (alveolar cell type II) of the lungs. 
ACE2 receptors are also abundantly found in the 
heart, liver, digestive organs, and kidneys. In fact, 
almost all endothelial and smooth muscle cells in our 
organ express ACE2; therefore, once virus enters the 
blood circulation, it spreads widely in the body [35]. 
All tissues and organs expressing ACE2 could be “the 
battlefield” of the CoV against immune cells. Based 
on Huang et al., (2020), most COVID-19 patients 
presented with dry cough, fever, dyspnea, and bilateral 
ground-glass opacities on chest computed tomography 
scans [20]. These COVID-19 infection characteristics 
bear a certain resemblance to SARS and MERS 
infections [36], [37] However, few patients with COVID-
19 infection had prominent upper respiratory tract signs 
and symptoms (such as rhinorrhea, sneezing, or sore 
throat), indicating that the target cells may be located 
in the lower airway. Based on Indonesian task force for 
COVID-19, most death cases related to airway problem 
(cough 17.3% and breathing difficulties 14.7%) [3]. 
Further, COVID-19 patients rarely developed intestinal 
signs and symptoms (like diarrhea), whereas about 
20–25% of patients with SARS or MERS infection had 
diarrhea [20], [37]; in Indonesia about 7.6–8.2% [3]. In 
severe form of COVID-19, CoV infection stimulates a 
cytokine storm that lead to acute respiratory distress 
syndrome (ARDS), acute cardiac injury, and secondary 
infection that lead to generalized sepsis thus multiorgan 
failure, which eventually lead to death [38]. Avoiding 
Figure  2:  Three-stage  classification  system proposed by Siddiqi HK and Mehra MR  [39],  recognizing  that  coronavirus  disease-19  illness 
exhibits three grades of increasing severity, which correspond with distinct clinical findings, response to therapy, and clinical outcome
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or modulating the cytokine storm maybe the key for 
treatment of severe/critical patients with COVID-19 
summarized in Figure 2 [39].
CPT
Desperation caused by COVID-19, the high 
mortality rate caused by ARDS that has not been 
successfully cured with conventional therapy and 
the increasing need for intensive care unit due to its 
accelerating number of ARDS sufferers has driven 
clinicians to try an alternative therapies with little or even 
no-evidence therapy previously (e.g., herbal medicine, 
cell-based therapy, and CPT). Convalescent plasma is 
a treatment that known for more than 100 years ago 
that the 1st time described in JAMA in 1893, when 
the German scientists used the serum from animal 
immunized against diphtheria to treat patients with the 
disease [21]. CPT also had been used against the 1918 
Spanish flu pandemic, measles, MERS, Ebola, and 
SARS [21]. CPT is considered as out-of-dated approach 
for modern diseases, such as COVID-19, compared 
with all the advanced technologies in medicine and the 
entire novel breakthrough in molecular biology that we 
know today.
CPT has emerged as a potential therapy for 
patients with severe COVID-19. The principle of CPT 
is to use antibodies from the healthy people who had 
recovered from COVID-19 (a.k.a convalescent); as 
antibody-rich in their plasma to provide neutralizing 
effects for high viral load and to calm down the cytokine 
storm in patients with severe COVID-19. CPT is 
particularly encouraged to utilize in patients with severe 
COVID-19 (ARDS) those have no other “effective” 
treatment. CPT are useful against emerging infectious 
agents if the latter induces neutralizing antibodies [40]. 
The effectiveness of CPT appears to differ depending 
on the pathogen and treatment protocols (e.g., timing, 
volume, and dosing of administration) [41]. CPT is not a 
novel concept. It has been applied to the prevention and 
treatment of many infectious diseases. The successful of 
CPT to treat the severe acute viral respiration infections 
brings optimism in the management of the COVID-
19 [12]. A meta-analysis from 32 studies of SARS 
and severe influenza showed a statistically significant 
reduction in the pooled odds of mortality following CPT, 
compared with placebo or no therapy (odds ratio, 0.25; 
95% CI) [40]. In 2014, the WHO suggested the use 
of CP obtained from patients recovering from Ebola 
virus disease (EVD) as an empirical treatment during 
outbreaks [42]; unfortunately, CPT was not associated 
with a significant improvement in survival for EVD. 
Recently, in 2019, there was published one report for 
randomized clinical trial (RCT) of 140 children and 
adults with influenza treated either CPT with high level 
of anti-influenza antibodies or to standard plasma. 
Those double-blind study concluded that the anti-
influenza CPT coffered no significant benefit superior 
versus standard plasma [43].
The Principle of Convalescent Blood 
Products Administration
After 10–14 days of infections usually 
followed by the clearance of viremia, this was the 
principle of convalescent blood products administration 
that usually performed after the initial symptoms to 
maximize efficacy [16]. Concurrent treatments might 
synergize or antagonize CPT efficacy (e.g., polyclonal 
intravenous immunoglobulins or steroids) [44]. Since 
the virological and clinical characteristics share similarity 
among SARS, MERS, and COVID-19, CPT might be 
a promising treatment option for COVID-19 rescue. 
The most critically ill patients show prolonged viremia 
(strongly correlated with serum IL-6 levels) which leaves 
room for the therapeutic intervention with antivirals and 
immunoglobulins even in late stages [45]. Viral shedding 
in survivors can be as long as 37 days, mandating SARS-
CoV-2 RNA screening in CP donors [46]. Appearance of 
serum IgM and IgA antibody in COVID-19 occurs since 
day 5 after symptom onset, while IgG is detected since 
day 14 but universally detected since day 20 [47], [48]. 
Severe female patients generate IgG earlier and higher 
titers [49]. The reason remains unknown but this could 
be detrimental consequences clinically; more chance 
of having transfusion-related acute lung injury (TRALI). 
Hence, the patients with resolved SARS-CoV-2 viral 
infection will develop significant serum antibody response 
(IgG) to different viral epitopes of the SARS-CoV-2 virus 
and some of these developed antibody responses in 
the host system will be likely to have the potential to 
neutralize the virus [12]. There is, currently, no evidence 
that people who have recovered from COVID-19 and 
have antibodies are protected from a second infection, 
as reported in china that seven cases of COVID-19 (three 
children and four adults) who was readmitted to hospital 
after recovered from COVID-19 [50]; as such issue rising 
the important to determining the efficacy of CPT.
The high level of antibody titers produced by 
the host immune system against the SARS-CoV-2 
virus significantly reduces the chances of getting 
re-infected [12]. Patients who have recovered from 
COVID-19 with a high neutralizing antibody titer may be 
a valuable donor source of CPT (1). However, duration 
of anti-SARS-CoV-2 antibodies in plasma remains 
unknown, though for other beta-CoVs immunity typically 
lasts 6–12 months [51]. Hence, a suitable donor could 
donate 600 mL plasma (equivalent to three therapeutic 
doses) every 14 days for a minimum of 6 months. In 
contrast to EVD, SARS, and MERS, most of COVID-
19 patients exhibit few or no symptoms and do not 
require hospitalization, suggesting that the majority of 
convalescent donors are best sought after in the general 
population [52]. Based on Indonesian COVID-19 CPT 
Task Force 2020, the appropriate donor [53], [54] and 
recipient [55] must meet the following conditions:
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Donor Recipient
a)  Tested positive COVID-19 through the 
results lab. examination and >3 weeks 
after the onset of COVID-19 symptoms
a) Positive COVID-19 results
b)  Complete symptom resolution at least 14 
days before donation plasma
b)  Having severe COVID-19 at least one 
of the signs: Dyspnea, respiratory 
frequency ≥30 breaths/min, blood O2 
saturation ≤93%, ratio arterial O2 partial 
pressure to inspired O2 fraction (PaO2/
FiO2) <300, and/or lung infiltrates > 50% 
in 24 or 48 h
c)  Age: 18–55 years old, and weight for 
male ≥50 kg, for female ≥45 kg
c)  Having critical COVID-19 at least 
one of the following circumstances: 
Respiratory failure (ratio of arterial O2 
partial pressure to inspired O2 fraction 
(PaO2/FiO2) <200), septic shock, and/or 
multiple organ dysfunction failure
d)  No history of blood-transmitted diseases d)  Can be given immediately to treated 
patients who complain shortness of 
breath
e)  Female donor must be negative towards 
HLA antibody (if not available HLA 
antibody tests can be from women who 
not ever pregnant) or male donors
e)  Not indicate for patients with mild 
COVID-19 (without symptoms of breath 
shortness, does not meet the criteria of 
severe or critical COVID-19)
f) Negative COVID-19 results f) Informed consent
g)  Determine the SARS-CoV-2 neutralizing 
antibody titer, if the examination can be 
performed (the optimal antibody titer is 
greater than 1:320)
h)  Eligible donors must be assessed by 
clinicians according to treatment
Based on Pei et al., (2020), CP was collected 
using fully automatic apheresis machine or a fully 
automatic blood cell separator (refer to technical operation 
procedure of blood station). The plasma volume taken 
was around 200–400 mL that the exact volume should 
be assessed by clinicians. The interval between plasma 
collections should be more than 2 weeks. The plasma 
was stored at 2–6°C for 48 h, while for long-term storage; 
it should be rapidly frozen at −20°C.
CPT, Do We Have All the Answer?
The first published report of CPT against 
COVID-19, a preliminary communication posted online 
on March 27, 2020, in JAMA for five seriously ill patients 
in China. Shen et al., (2020), reported in all five patients, 
who were critically ill with COVID-19, after treated with 
CPT shown the body temperature normalized within 3 
days in four of five patients, the Sequential Organ Failure 
Assessment score decreased, and PaO2/FiO2 increased 
within 12 days (around 172–276 before treatment 
and 284–366 after treatment) [56]. Furthermore, viral 
loads decreased and became negative within 12 
days of transfusion and SARS-CoV-2-specific ELISA 
and neutralizing antibodies titers increased after the 
transfusion (around 40–60 before treatment and 80–320 
after treatment on day 7). Furthermore, at 12 days after 
transfusion, ARDS was resolved in four patients. Within 
2 weeks of treatment, three patients were weaned 
from mechanical ventilation. From five patients, three 
patients have been discharged from hospital (length of 
stay: 53, 51, and 55 days) and two patients are in stable 
condition at 37 days after transfusion. Two more reports 
from Wuhan, published on April 6 and April 15, 2020, 
respectively [1], [57]. All those reported the therapy 
save lives and looking for continuing with randomized 
controlled trial to confirm the results.
The US Food and Drug Administration (FDA) 
first announce on March 24, 2020; in more details on 
April 3, and April 13, 2020, respectively, that FDA would 
facilitate access to CP for treating COVID-19. The 
FDA cautioned “It is therefore important to determine 
through clinical trials, before routinely administrating 
CPT to the patient with COVID-19, that it is safe and 
effective.” CPT is one good option, but it not without 
risk. The COVID-19 may cause increasing clotting; 
Plasma is rich with clotting factors and typically used 
to reverse bleeding problems, so theoretically CPT 
could increase clotting risk in patients with COVID-19 
without any promise of benefit (plasma also promote 
anti-coagulation) [58]. In additional, plasma transfusion 
is also associated with adverse event, ranging from 
mild fever and allergic reaction (e.g., plasma protein, 
sodium citrate, or selective IgA deficiency) to life-
threatening bronchospasm, TRALI (male donors 
are usually preferred to avoid the risk of transfusing 
anti-HLA/HNA/HPA antibodies from parous women; 
as anti-HLA/HNA/HPA antibody screening should be 
performed), and antibody-dependent enhancement 
that will leads to enhanced infection and transfusion 
associated circulatory overload (TACO) such as in 
patients with cardiorespiratory disorder, old age, 
or renal impairment [59]; also chance the risk of 
transfusion-transmitted infectious (TTI), as pathogen 
inactivation combine with nucleic acid testing can 
reduced TTIs.
There is a lack of RCTs investigating CPT as 
a potential therapy for COVID-19, though observational 
studies have reported some promising benefits. There 
were two RCTs [60], [61], that were published after 
being terminated early. The first RCT was conducted 
in Wuhan, China, February to April 2020. It was 
comparing the standard treatment (n = 52) versus the 
effect of CPT (n = 51); with two patients reported an 
adverse events [60]. Ultimately, there was no significant 
effect of CPT on the primary outcome of time to clinical 
improvement within 28 days [60]. The second RCT, 
conducted in the Erasmus MC, Netherlands [61]. It was 
comparing the standard treatment (n = 43) versus the 
effect of CPT (n = 43); hence, somewhat unsurprisingly, 
there was no effect of treatment on mortality, hospital 
length of stay or disease severity [61].
In addition, an initial safety assessment of 5000 
patients who received CPT in the USA demonstrated a 
0.08% mortality, 0.14% TACO, 0.22 TRALI, and 0.06% 
severe allergic transfusion reaction; with over all <1% 
rate of serious adverse events immediately following 
treatment, indicating that the risks of CPT are likely 
not excessive relative to the risks of severe COVID-
19 [62]. Another larger study of 138 CPT patients who 
were compared with 1430 patients receiving standard 
therapy showed promising benefits such as reduced 
mortality and reduced proportion of patients exhibiting 
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shortness of breath, somehow there were three patients 
experienced minor allergic [63]. Despite the above 
studies reporting positive and negatives outcomes, pro 
versus contra; it is clear that additional RCTs and global 
action are required.
Conclusion
There are so many of potential candidate 
treatment that are so promising in theory but somehow fall 
apart when translated into real-clinical study; only time will 
tell, including our ongoing CPT clinical study. All of these 
CPT against a massively COVID-19 infection is “imperfect 
Science,” and YES, we do not have all the answer; but its’ 
worth to trying rather than dying doing nothing.
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